AstraZeneca PLC (AZN)
Stockholm Exchange · Sweden · prices in SEK · close of 22 Oct 2026
Key indicators
| Last close | SEK 1,713.50 |
|---|---|
| 52-week range | 1,467.00 – 1,925.50 |
| Return, 1 month / 3 months | +2.8% / +4.6% |
| Return, 1 year / 3 years | +10.6% / +29.0% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 26.0% |
| Worst drawdown (1 year) | -22.5% |
| Average daily value traded | 940.85M SEK |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AstraZeneca is a pharmaceutical company that researches, develops and markets prescription medicines. Its products treat conditions in areas such as cancer, heart and blood vessel disease, respiratory illness and diabetes, and are prescribed by doctors and used in hospitals and clinics. The company has its headquarters in Cambridge, England, and a substantial presence in Sweden, reflecting its British and Swedish origins. It serves patients and healthcare systems in many countries around the world.
On this site AstraZeneca PLC appears as a stock on the Stockholm Exchange (Sweden), code AZN, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AstraZeneca PLC (AZN) trades on the Stockholm Exchange in Sweden. It last closed at SEK 1,713.50 on 22 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 159 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.6% and over the last three months it rose 4.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.3% | ||
| From 52-week high | -10.0% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 4.6% | ||
| 6-month return | -4.5% | ||
| 12-month return, skipping the last month | 7.6% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.5% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 940.85M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 43 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | +2.8% |
| 3 months | +4.6% |
| 6 months | −4.5% |
| 1 year | +10.6% |
| 3 years | +29.0% |
| 5 years | +78.7% |
Signals
| 50-day / 200-day average | 1,593.68 / 1,691.84 |
|---|---|
| Golden / death cross (60 days) | Death, 59 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 38.61 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | SEK 10.3200 |
| 19 Feb 2026 | SEK 19.4900 |
| 7 Aug 2025 | SEK 9.8723 |
| 20 Feb 2025 | SEK 22.6321 |
| 8 Aug 2024 | SEK 10.3929 |
| 22 Feb 2024 | SEK 20.3523 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.